Green Cross eying sales of 50 billion won with new drug

Green Cross Corp. said Friday it has signed a co-promotion agreement with LG Life Sciences to market “Shinbaro,” a new drug for osteoarthritis in a bid to raise 50 billion won in domestic sales within the next five years.

Shinbaro is Korea’s fourth homegrown osteoarthritis medicine containing six herbs, such as Cibotium barometz J. Smith and Saposhnikovia divaricata Schiskin, and its efficac...